Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
17 janv. 2023 09h00 HE
|
Assertio Holdings, Inc.
SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and olderOral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
09 janv. 2023 16h15 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 janv. 2023 16h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco
13 déc. 2022 14h07 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million
05 déc. 2022 07h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports Third Quarter 2022 Financial Results
08 nov. 2022 16h01 HE
|
Assertio Holdings, Inc.
Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36%Increases Guidance for Net Product Sales and Adjusted EBITDADebt Refinancing Extends Maturity, Reduces Cost and...
Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
27 oct. 2022 16h05 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
27 oct. 2022 09h00 HE
|
Assertio Holdings, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) --...
Assertio to Participate in October 2022 Investor Conferences
12 oct. 2022 07h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio to Participate in the 2022 Lake Street BIG6 Conference
07 sept. 2022 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...